London, UK – 3rd November 2025: Closed Loop Medicine (“CLM”) today announced the allowance of a key U.S. patent (U.S. App. No. 18/734,284 Titled – ‘Dosing of Incretin Drugs’) that adds additional protection to its proprietary AI-based adaptive dosing technology for GLP-1 therapies. The patent approval which will now proceed to Grant, strengthens CLM’s capability to deliver individualized, data-enabled treatment pathways that improve patient outcomes and can enhance the value of pharmaceutical pipelines.

Kate Woolland, Chief Executive Officer at Closed Loop Medicine said “CLM is positioned to help shape the future of GLP-1 therapy, supported by its newly granted patent covering personalised and adaptive dosing of semaglutide and other incretins through our broader IP portfolio. “Pharma companies are rapidly shifting toward data-connected, patient-directed engagement of their products, whilst tech companies are increasing working to deliver technology and services that satisfy the need of patients to manage their own health. CLM is ideally placed to contribute to both of these approaches and we look forward to accelerated partnering discussions with both groups”

This patent provides broad protection for CLM’s approach to personalised dosing of semaglutide, describing how the right dose can be calculated for each patient based on their current and target weight. However, it then goes on to cover more advanced versions of this method, where the dosing algorithm can use machine learning and pharmacokinetic (drug concentration) models to fine-tune initial and follow-on doses, and enable dose titration.

Over time, the system becomes increasingly precise by learning from each patient’s data, including through analysis of changes in weight, energy intake, and energy expenditure. Importantly, the patent also covers the use of a closed-loop feedback system, where patient progress data feeds directly back into CLM’s adaptive therapy platform to automatically provide optimised dosing recommendations; thereby, creating a continuously learning, responsive and highly personalized treatment model.

Dr Paul Goldsmith, Chief Medical Officer, Closed Loop Medicine added “Through modelling semaglutide and tirzepatide as pathfinder drugs, we demonstrated how AI can make dose adjustment automatic, safer, and more effective for GLP-1 agonists. Our data validates this core approach, and through this patent allowance its inventive nature is recognised as we continue to pursue extended utility for the technology and broad protection for this full class of therapies and combinations, including through separate patent families and continuation applications.”

Whilst the specific patent claims of 18/734,284 relate to semaglutide, the allowance of these claims indicates the patentability of CLM’s general concept of personalized dosing, based on patient weight, applied to all GLP-1 drugs. CLM is, therefore, actively filing a continuation application for protection of other GLP-1 agonists and related incretins.

In September, CLM launched WeDosify, a GLP-1 dosing tool that represents the first real-world use of this patented technology. WeDosify personalizes titration in real-world settings, and CLM is now working towards a fully automated version that further exploits its IP estate, enabling a patient to receive personalized support throughout their GLP-1 journey with minimal clinical intervention. With compounding pharmacies exploiting novel doses and with micro-dosing programmes springing up across the US there is already demand for dose optimization.

About Closed Loop Medicine

Closed Loop Medicine (CLM) Ltd is a UK-based personalized-dosing company integrating software, data, and drug therapy to optimise treatment efficacy and tolerability on an individual basis.

CLM’s incretin portfolio now includes 3 granted or allowed families and an additional 3 pending patent families, with Continuations and Continuations in Part additions planned, in addition to its existing broader IP portfolio covering its platform software approach and drug related patents in other therapy areas.

For more information, visit www.closedloopmedicine.com, and follow Closed Loop Medicine on LinkedIn.